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A. Viti, MD,* and A. Mussi, MD*
(J Thorac Oncol. 2007;2: Suppl 1, 37)
We previously reported the positive results we achievedin detecting sentinel lymph node (SLN) and in identi-
fying micrometastases by immunohistochemistry (IHC) re-
search of cytokeratin in patients with stage I non-small cell
lung cancer (NSCLC).
OBJECTIVE
We applied a new protocol, which includes polymerase
chain reaction (PCR) for RNA detection of cytokeratin 7 and
19, to all the SLNs, to detect micrometastases and to define an
improvement of staging.
METHODS
Since January 2005, we have applied the SLN technique
to 22 patients. The peri-lesional injection of 99mTc-nanocolloid
suspension was performed under computed tomographic guid-
ance (seven cases), with fiberoptic broncoscopy (five cases),
with thoracoscopy (two cases), and after thoracotomy (eight
cases). In three cases, the intraoperative pathological evaluation
identified a benign lesion; therefore the RT-PCR molecular
staging technique was not applied. In the other cases, resection
with mediastinal lymph node dissection was performed. The
SLN was divided into two parts: one was frozen for PCR study,
the other was fixed and paraffin-embedded for IHC.
RESULTS
We identified SLNs in 16 patients with NSCLC (85%).
In three patients, we were unable to identify the SLN,
probably because the 99mTc-nanocolloid suspension had
been injected within the tumor and not at the edges, and
migration had been impaired by the peritumoral fibrous-
inflammatory reaction. Routine pathology evaluation showed
stage I disease in 13 patients, T3N0 in one patient, and N2
disease in five patients. In seven patients, IHC identified
lymph node metastasis (two cases resulted in N0 according to
routine pathology). RT-PCR analysis was performed in 10
patients: in six patients, micrometastases were identified
(three resulted in N0 according to routine pathology; one
remained N0 even after IHC evaluation). Three micrometa-
static NSCLC were therefore identified. The “skip-metastasis
phenomenon” was not observed in this series. Three patients
with N2 disease relapsed. One patient with N0 disease per
classic pathology and IHC but with RT-PCR identification of
micrometastases experienced systemic relapse 3 months after
surgery.
CONCLUSIONS
The SLN technique was able to provide a subgroup of
patients for whom the use of expensive molecular procedures,
such as RT-PCR, could be applied on a well-focused target
(the SLN). This approach could improve the accuracy of
pathologic staging in identifying a subset of patients with a
higher risk of relapse.
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